Melanoma Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.


Protocol No.PITitle
OSU-07030William CarsonAnalysis of Micro-RNA Species in Melanoma.
OSU-13023William CarsonA Pilot Study of Beta-Blockers in Patients with Advanced Cancer
OSU-13114William CarsonA Storage Facility for Tissues Obtained from Patients with Malignant Melanoma.
OSU-11099William CarsonIdentifying CT Imaging Biomarkers to Predict Disease Outcome in Melanoma on Anti-angiogenic Therapy
OSU-11166William CarsonA Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients with Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
OSU-0358Frederick DavidorfMolecular Genetic Profiling of Uveal Melanomas
OSU-06036Frederick DavidorfGenetics of Hereditary Uveal Melanoma.
OSU-11024Kari KendraBRF114144: A Rollover Study to Provide Continued Treatment with GSK2118436 to Subjects with BRAF Mutation-Positive Tumor
SWOG-S1320Kari KendraA Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
OSU-13124Kari KendraA Phase I expansion cohort evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in patients with unresectable melanoma
SWOG-S1221Kari KendraPhase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer
OSU-13210Kari KendraThe NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma
OSU-12093Quan LiIncidence of febrile neutropenia for metastatic melanoma patients receiving CVD without prophylactic granulocyte-stimulating factor (GCSF)
OSU-12087Thomas OlenckiA PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT PATTERNS AND EFFECTIVENESS AND SAFETY OUTCOMES IN ADVANCED BASAL CELL CARCINOMA AND BASAL CELL CARCINOMA NEVUS SYNDROME PATIENTS
ALLIANCE-A091201Thomas OlenckiRandomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
OSU-12055Alicia TerandoFeasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma
OSU-08070Traci WilgusVascular Endothelial Growth Facto Signaling in Skin Carcinogenesis
OSU-12118Evan WuthrickPHASE I STUDY OF IPILIMUMAB COMBINED WITH WHOLE BRAIN RADIATION THERAPY OR RADIOSURGERY FOR MELANOMA PATIENTS WITH BRAIN METASTASES
OSU-12182Evan WuthrickA phase 2 study using stereotactic ablative radiation therapy and ipilimumab in patients with oligometastatic melanoma

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu